Drug intelligence / Profile preview

Ciclo 21

Development stage
Phase 3
Lead developer
União Química
Modality
Small Molecules
Administration
Oral
01

Overview

Ciclo 21 is a combined oral contraceptive (COC) containing a fixed-dose combination of 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol. Manufactured by the Brazilian pharmaceutical company União Química, it is used for the prevention of pregnancy and acts as a generic equivalent to the reference drug Nordette. The medication functions by suppressing the release of pituitary gonadotropins, specifically luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which inhibits follicular maturation and prevents ovulation. Furthermore, it increases the viscosity of cervical mucus to hinder sperm penetration and alters the endometrial lining to decrease the probability of implantation. It is typically administered as a once-daily pill for 21 consecutive days followed by a 7-day hormone-free interval.

Brand names
Ciclo 21Ciclo21Ciclo-21
Other names
levonorgestrel + ethinyl estradiolLNG+EE2
02

Targets

PR (Progesterone receptor)ER (Estrogen receptor)

Beyond the preview

Go deeper on Ciclo 21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ciclo 21.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call